|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The possible use of PFKP as a diagnostic marker or a drug target in the prevention or treatment of cancer is also discussed.
|
30919341 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The possible use of PFKP as a diagnostic marker or a drug target in the prevention or treatment of cancer is also discussed.
|
30919341 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, the Snail-PFKP axis plays an important role in cancer cell survival via regulation of glucose flux between glycolysis and PPP.
|
28176759 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, the Snail-PFKP axis plays an important role in cancer cell survival via regulation of glucose flux between glycolysis and PPP.
|
28176759 |
2017 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations.
|
25985179 |
2015 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations.
|
25985179 |
2015 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3), an enzyme producing fructose 2, 6-bisphosphate (F-2, 6-BP), serves as a switch to activate phosphofructokinase-1, and is a critical enzyme for endothelial glycolysis, mediating circadian control of carcinogenesis.
|
31209811 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis.
|
29038421 |
2017 |
|
Obesity
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The INSIG2 rs7566605 and PFKP rs6602024 polymorphisms play no apparent role in the development of common forms of obesity in the Danish population.
|
18682847 |
2008 |
|
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study also provided supportive evidence for previously identified associations between obesity and INSIG2 and PFKP, but not FTO.
|
18325910 |
2008 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Considering that PFKP is a crucial player in many steps of cancer initiation and metastasis, we reviewed the specificities and complexities of PFKP and its biological roles in human diseases, especially malignant tumors.
|
30919341 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1.
|
30778058 |
2019 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Notably, the high expression of PFKP was observed more frequently in patients with IDH-mutant ICC compared to in those with wild-type IDH (p < 0.01, 80.9% vs. 42.5%, respectively).
|
31827136 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1.
|
30778058 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In addition, PFKP expression was significantly increased in OSCC patients and its upregulation was associated with the presence of tumor pathological differentiation and lymph node metastasis.
|
29894707 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, PFKP expression was significantly increased in OSCC patients and its upregulation was associated with the presence of tumor pathological differentiation and lymph node metastasis.
|
29894707 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Support for essential involvement of β-catenin and PFKP in lactate production and migration/invasion was obtained by siRNA knockdown of their expression.
|
29069720 |
2017 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
When stratified by tumor histology, three SNPs (ENO1 rs2274971A > G, PFKM rs11168417C > T, and PDK2 rs3785921G > A) were significantly associated with OS and/or DFS only in squamous cell carcinoma, whereas PFKP rs1132173C > T exhibited a significant association with survival outcomes only in adenocarcinoma.
|
27767175 |
2016 |
|
Situs ambiguus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Morpholino loss-of-function experiments in Xenopus support a role for one of these novel candidates, the platelet isoform of phosphofructokinase-1 (PFKP) in heterotaxy.
|
27821535 |
2016 |
|
HER2-positive carcinoma of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Future clinical studies focusing on these genes, as well as on homeobox-containing genes and HER2, AKT3, HK1, and PFKP, are warranted which could provide further insights into the biology of HER2+ breast cancer.
|
25089541 |
2014 |
|
HER2-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Future clinical studies focusing on these genes, as well as on homeobox-containing genes and HER2, AKT3, HK1, and PFKP, are warranted which could provide further insights into the biology of HER2+ breast cancer.
|
25089541 |
2014 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells.
|
20483646 |
2010 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells.
|
20483646 |
2010 |
|
Renal tubular acidosis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Human H+ATPase a4 subunit mutations causing renal tubular acidosis reveal a role for interaction with phosphofructokinase-1.
|
18632794 |
2008 |